Jutro Medical, a Warsaw-based healthcare provider focused on integrating AI into primary care, has secured €12 million in Series A funding to expand its services across Europe, starting with a new clinic in the Netherlands. The funding round was led by KAYA VC and RIO ASI, with support from existing investor Inovo VC and a debt component from mBank. Founded in 2020, Jutro Medical serves 70,000 patients, boasting a high satisfaction rating. The clinic uses AI agents to handle over 68% of teleconsultations, making appointments quicker and allowing doctors to focus on patient care. Plans for expansion aim to reach 350,000 patients in the next two years while maintaining high-quality care across Europe’s public health system.
Warsaw-based Jutro Medical, an innovative primary care provider that leverages artificial intelligence, has successfully raised €12 million in a Series A funding round. This financial boost aims to enhance its services across Europe, with plans to open its first clinic in the Netherlands soon.
KAYA VC and RIO ASI led the funding round, with continued support from existing investor Inovo VC, and included a debt component from mBank. Jutro Medical’s CEO, Adam Janczewski, emphasized the importance of AI in streamlining healthcare delivery by automating routine tasks, allowing medical professionals to focus on patient care.
Since its inception in 2020, Jutro Medical has served over 70,000 patients, recording stellar ratings. With a remarkable average visit rating of 4.93 on a 1–5 scale and a Net Promoter Score (NPS) of 86, the company’s commitment to quality care is evident.
Jutro Medical utilizes AI agents capable of managing approximately 68% of teleconsultations. This means that patients can interact with an AI agent at the start of their appointments to gather necessary information, dramatically reducing the time doctors spend on administrative tasks. While these AI interactions enhance efficiency, doctors remain responsible for all medical decisions, ensuring patient safety and confidentiality.
The funding will enable Jutro Medical to extend its reach, with a goal of serving 350,000 European patients in the next two years. The company aims to revolutionize primary care in Europe by integrating AI with traditional healthcare practices, providing superior medical services under public health insurance.
Experts in healthcare management, including Bartosz Skawiński and Marek Maleszyk, have joined Jutro Medical, bringing valuable experience to enhance service delivery and operational efficiency. Their commitment to transforming healthcare ensures that Jutro Medical stays at the forefront of innovation in primary care.
In summary, Jutro Medical is setting new standards in primary care by harnessing the power of AI, aiming to provide accessible and high-quality healthcare across Europe.
Tags: Jutro Medical, AI in healthcare, primary care, healthcare innovation, Series A funding, European healthcare.
What is Jutro Medical doing with its €12 million funding?
Jutro Medical is using the €12 million they raised to develop AI agents that will replace traditional telemedicine. These AI agents will help provide healthcare services more efficiently and effectively.
How do these AI agents work?
The AI agents will use advanced technology to understand patients’ needs and provide medical advice. They can ask questions, analyze symptoms, and offer recommendations, making healthcare easier and faster for everyone.
What are the benefits of using AI instead of telemedicine?
Using AI can make healthcare more accessible and quicker. It can reduce waiting times for patients and allow healthcare providers to focus on more complex issues, improving overall care.
Will patients still talk to real doctors?
Yes, patients can still see real doctors when needed. The AI agents are here to support and streamline the process, so doctors can spend more time on serious cases while AI handles simpler questions.
When can we expect to see these AI agents in action?
While specific timelines are not available, Jutro Medical is working hard to develop and test these agents. They aim to bring them to healthcare settings as soon as possible to improve patient experiences.
